Speaking of delusional. This board discussed a combination pill years ago and while it might be a nice niche product is did not deserve high priority as there are numerous drawbacks given the issues of pill size, statin brand, satin dosage etc.
I hope it offers consumers and docs a nice choice but to pretend it was somehow a huge management oversight/failing to wait till now is dumb. It was Du, COVID, the appeals court, Nisan and consumer reluctance to embrace another not low-cost drug that left us with s $3 SP.
I sure hope Denner knows a great deal more than any of us think we know. I can't imagine that Denner would want anything from AMRN except a BP BO. GIA (which includes partnering) is suicide. I can't see any benefit for a combo-pill unless it were a one-a-day version using Mochida's version. Nearly four years ago AMRN announced its collaboration with Mochida. What has this produced for AMRN? I honestly do not trust KM's stated strategy will work if a GIA mode is maintained. I would rather a BP acquirer make important strategic decisions rather KM. KM does not seem to have the aggressiveness that I had hoped he would have. Who would us shareholders rather have running this company? KM or Denner? Who do we think would a better return for shareholders?
Market Data 
Markets 
AI
